DOCSLIB.ORG

United States Patent Office Patented Oct

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent Office Patented Oct 3,346,562 United States Patent Office Patented Oct. 10, 1967 2 3,346,562 cg METHOD FOR THE PRODUCTION OF PO-CE Base RBONUCLEOSDE-5'-PHOSPHATE / O Mikio Honjo, Takatsuki, and Ryuji Maremoto, Minoo, Cl EO Japan, assignors to Takeda Chemical industries, Ltd., Osaka, Japan No Drawing. Filed May 31, 1966, Ser. No. 553,718 Claims priority, application Japan, May 29, 1965, R. X R. 40/31,814 9 Claims. (Cl. 260-21.5) HO. O. BIO O 10 N1 N1 This invention is concerned with a method for the pro Po-H, Base Po-H, Base duction of ribonucleoside-5'-phosphate. EIO k" wE+ EO k". Ribonucleoside-5'-phosphate is very useful as condi H HO - ment for food and also in the pharmaceutical industry, O O OH OH and has been chemically produced by at first protecting 15 X the hydroxyl groups at the 2'- and 3'-positions of its ribose R1 R2 moiety with acyl or isopropylidene groups and then phos phorylating the 5'-hydroxyl group of the thus-protected RN compound with pentavalent phosphorus compound such C=O: aliphatic ketone or aromatic aldehyde as phosphorus pentachloride, phosphorus oxychloride, 20 R?2 etc., followed by removing the protecting groups. As "ribonucleoside' in the present method there are However, this hitherto-known method requires a long used those containing purine base such as adenosine, time (about 7 to about 30 hours) for completing the pro inosine, etc. or those containing pyrimidine base such as tection and phosphorylation, and therefore is not desirable uridine, cytidine, etc. As the aliphatic ketone having 3 from an industrial viewpoint. 25 to 6 carbon atoms, there is employed acetone, methyl The present invention is addressed to the problem of ethyl ketone, methyl isobutyl ketone, methyl, isopropyl providing an industrially feasible method for the chemical ketone, etc., and as aromatic aldehyde there is used e.g. preparation of ribonucleoside-5'-phosphate and is based benzaldehyde, tolualdehyde or naphthaldehyde. on the discovery that a selective phosphorylation of the Generally, the reaction is carried out by first dissolving 5'-hydroxyl group of the ribonucleoside can easily be 30 or suspending the ribonucleoside into ketone or aldehyde completed in a short time by allowing the ribonucleoside and then adding phosphorus trichloride and water to the to react with ketone or aldehyde and phosphorus trichlo thus-prepared solution or suspension, leaving the reaction ride in the presence of water and oxygen. w system in contact with the atmosphere or blowing oxygen The object of the present invention is thus to provide or gas containing oxygen, such as air, into the reaction a novel and commercially practical method for the pro 35 system. duction of ribonucleoside-5'-phosphate. As the ketone or aldehyde acts as a solvent, no other Another object of the invention is to chemically pro reaction solvent need be used. The ketone or aldehyde duce ribonucleoside-5'-phosphate in a short time and in a is used in such a volume as sufficiently dissolves or sus good yield from the corresponding ribonucleoside. 40 pends the ribonucleoside and preferably is used in a Briefly stated, the present method comprises allowing large excess. the ribonucleoside to react with phosphorus trichloride The mole ratio of phosphorus trichloride and water to and aliphatic ketone having 3 to 6 carbon atoms or aro the nucleoside may vary depending on the starting ma matic aldehyde in the presence of water and oxygen, and terial, and generally ranges from about 10 to about 100 subsequently hydrolyzing the resulting product into ribo moles, preferably about 40 to about 60 moles, of phos nucleoside-5'-phosphate. The determinative factor is the 45 phorus trichloride and about 2 to about 20 moles, pref use of phosphorus trichloride, i.e. a compound with tri erably about 2 to about 4 moles, of water per one mole valent phosphorus, as a starting material. of the ribonucleoside. In this method, the reaction appears to proceed accord All the necessary amount of phosphorus trichloride can ing to the following reaction scheme: be added to the reaction system at one time, but a much 50 better yield is realized by adding the phosphorus tri HO CH Base HO CH Base chloride to the reaction system in two batches. The latter O N R N PCls O N PCls procedure is carried out by adding at first about 1 to about -- C=O -\ -b / H2O - 10 moles (desirably 1 to 2) of phosphorus trichloride 55 per one mole of ribonucleoside together with about 2 to OH OE Ra ". about 20 moles (desirably 2 to 4) of water per one mole / of ribonucleoside to the reaction system to allow the re R. R. action to take place until the reaction mixture becomes c R clear, and then to add about 10 to about 90 moles (de P-O-CH Base C= 60 sirably 40 to 60) of the phosphorus trichloride per one mole of ribonucleoside to the reaction mixture to further c? - k"> R2 continue the reaction. In this case, the first reaction step - PC3 does not necessarily require oxygen, but the latter reac O O O2 tion step must be carried out while contacting the reac-. X. 65 tion system with the atmosphere or while blowing in oxy R. R. gen, air or the like. 3,346,562 3. 4. The reaction is advantageously carried out under cool phoresis (0.05 mol borate buffer) showed that inosine ing, e.g., at a temperature of about 0 to about 10° C. 5'-monophosphate was produced in the yield of 88%. In the present method, the hydroxyl groups at the 2'- Methanol was added to the concentrate to give 3.3 parts and 3'-positions on the ribose moiety are protected with by weight of disodium salt of inosine-5'-monophosphate. the aliphatic ketone or aromatic aldehyde in the presence 5 (Yield was 81%.) of phosphorus trichloride and water, and the free 5'- hydroxyl group is selectively phosphorylated by phos Example 2 phorus trichloride and oxygen in the presence of aliphatic After a mixture of 2 parts by weight of adenosine ketone or aromatic aldehyde. dissolved in 50 parts by volume of acetone, 4 parts by Thus the corresponding protected ribonucleoside 5'- Volume of phosphorus trichloride and 2 parts by volume phosphorus chloride ester is obtained. The protected com 10 of water was allowed to react in the same way as in pound is then subjected to hydrolysis into ribonucleoside Example 1, 45 parts by volume of phosphorus trichloride 5'-phosphate, for example, by adding the resulting product was further added to the reaction mixture. Thus obtained into ice water and adding alkaline material (e.g., sodium reaction mixture was treated in the same way as in hydroxide, potassium hydroxide, sodium carbonate, etc.) Example 1 to give 2.3 parts by weight of disodium salt of to adjust the pH value to 1.0-2.0, and then heating the 5'-adenylic acid. Yield was 61%. mixture at about 40 to 100° C., preferably 50 to 80° C. Example 3 Thus-resulting final product, i.e., ribonucleoside 5'- phosphate, can be isolated from the reaction mixture, for After a mixture of 2 parts by weight of cytidine example, by means of using ion-exchange resins or acti dissolved in 100 parts by volume of acetone, 3 parts by vated carbon, or by crystalizing in a form of salt such as Volume of phosphorus trichloride and 1 part by volume sodium salt. of Water was allowed to react in the same way as in As detailed above, by the present invention, ribonu Example 1, 50 parts by volume of phosphorus trichloride cleoside-5'-phosphate can be chemically produced in a was further added to the reaction mixture. The thus short time and in good yield by very simple procedure. obtained reaction mixture was treated in the same way as For the purpose of showing the reaction time required in Example 1 to give 2.8 parts by weight of disodium salt for the present method, the following illustrative test data of 5'-cytidylic acid. Yield was 75%. is given: Example 4 Test data.--To a suspension of 2 grams of inosine in 50 milliliters of acetone were added 3 milliliters of phos 30 The mixture of 2 parts by weight of inosine, 4 parts by phorus trichloride and then 1 milliliter of water. The re volume of phosphorus trichloride, 20 parts by volume of action mixture was stirred for 30 minutes under 20° C. benzaldehyde and 2 parts by volume of water was treated 50 milliliters of phosphorus trichloride were then further in the same way as in Example 1. 40 parts by volume of added into the reaction mixture at 0 to 5 C. 0.1 milliliter phosphorus trichloride was added to the reaction mixture. test samples of the reaction solution were taken out at 3 5 The thus-obtained reaction mixture was treated in the suitable intervals of time to check upon on the forma same way as in Example 1 to give 1.4 parts by weight of tion of inosine-5'-monophosphate (hereinafter referred to disodium salt of 5'-inosinic acid. (Yield 34%.) as 5'-IMP). The result is shown in the following table. Example 5 The formation of 5'-IMP shows a fixed percentage (93%) at 60 minutes after the start of reaction. 40 To a suspension of 2 parts by weight of inosine in 50 parts by volume of acetone were added 3 parts by volume Formation of phosphorus trichloride and then 1 part by volume of Time (minutes): of 5'-IMP, percent Water.
Load more

Recommended publications
  • Phosphorus Oxychloride CAS No
    Product Safety Summary Phosphorus Oxychloride CAS No. 10025-87-3 This Product Safety Summary is intended to provide a general overview of the chemical substance. The information in the summary is basic information and is not intended to provide emergency response information, medical information or treatment information. The summary should not be used to provide in-depth safety and health information. In-depth safety and health information can be found in the Safety Data Sheet (SDS) for the chemical substance. Names Phosphorus oxychloride Phosphorus trichloride oxide Phosphoric trichloride POCl 3 Product Overview Solvay Novecare does not sell phosphorus oxychloride directly to consumers. Phosphorus oxychloride (POCl3) is used as a chemical intermediate to produce a variety of products which are used in several applications including manufacture of triarylphosphate esters which are used as flame retardants as well as an intermediate in the production of pharmaceutical, textile and agricultural chemicals. Phosphorus oxychloride is used in industrial applications and other processes where workplace exposures can occur. Consumer exposure does not occur as phosphorus oxychloride is not used in any commercially available product. Phosphorus oxychloride is dangerous to human health. Phosphorus oxychloride may be fatal if inhaled, highly toxic if swallowed, harmful if absorbed through skin and can cause severe burns which may result in scarring. Phosphorus oxychloride is consumed in manufacturing processes. POCl3 can make its way into the environment through unintentional releases (spills). POCl3 will not bioaccumulate but is not biodegradable. POCl3 in higher concentrations can be harmful to aquatic life due to formation of acids from the hydrolysis of POCl3. When released into the atmosphere, phosphorus oxychloride exists as vapor.
    [Show full text]
  • 5 Phosphorus Oxychloride1 Acute Exposure Guideline Levels
    Acute Exposure Guideline Levels for Selected Airborne Chemicals: Volume 10 Committee on Acute Exposure Guideline Levels Committee on Toxicology Board on Environmental Studies and Toxicology Division on Earth and Life Studies Copyright © National Academy of Sciences. All rights reserved. Acute Exposure Guideline Levels for Selected Airborne Chemicals: Volume 10 THE NATIONAL ACADEMIES PRESS 500 FIFTH STREET, NW WASHINGTON, DC 20001 NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Insti- tute of Medicine. The members of the committee responsible for the report were chosen for their special competences and with regard for appropriate balance. This project was supported by Contract No. W81K04-06-D-0023 and EP-W-09-007 be- tween the National Academy of Sciences and the U.S. Department of Defense and the U.S. Environmental Protection Agency. Any opinions, findings, conclusions, or recom- mendations expressed in this publication are those of the author(s) and do not necessarily reflect the view of the organizations or agencies that provided support for this project. International Standard Book Number-13: 978-0-309-21987-7 International Standard Book Number-10: 0-309-21987-6 Additional copies of this report are available from The National Academies Press 500 Fifth Street, NW Box 285 Washington, DC 20055 800-624-6242 202-334-3313 (in the Washington metropolitan area) http://www.nap.edu Copyright 2011 by the National Academy of Sciences.
    [Show full text]
  • NPR72: the Pavlodar Chemical Weapons Plant in Kazakhstan
    GULBARSHYN BOZHEYEVA Report The Pavlodar Chemical Weapons Plant in Kazakhstan: History and Legacy GULBARSHYN BOZHEYEVA Gulbarshyn Bozheyeva holds a Ph.D. degree in Chemical Physics from the Kazakh State University. From 1996-97, she was a Visiting Scholar and Research Associate at the Center for Nonproliferation Studies at the Monterey Institute of International Studies. She is now completing a master’s degree in International Development Policy at Duke University. he former Soviet Union’s chemical weapons theless, manufacturing lines and equipment for primary (CW) program consisted of many production and intermediate CW precursors and buildings for fill- plants that created the world’s largest stockpile ing CW munitions were constructed at Pavlodar. The T 1 of chemical weapons. Most of the CW production and plant also acquired personnel with expertise in CW pro- storage facilities were located in Russia, but a few fa- duction.5 cilities existed in other Soviet republics. In recent years, This report is devoted to the role of the Pavlodar Western countries have provided significant financial Chemical Plant in the former Soviet CW program and assistance for dismantling former CW facilities in Rus- its current status. The first part of the report describes sia and converting former CW production facilities for the history of the Pavlodar plant and its military and 2 commercial use. Although a fair amount has been writ- civilian infrastructures. The second part deals with the ten about Russian CW facilities, little is known about CW capability of the plant and the nature of the chemi- the CW programs in other former Soviet republics.
    [Show full text]
  • Particularly Hazardous Substances
    Particularly Hazardous Substances In its Laboratory Standard, OSHA requires the establishment of additional protections for persons working with "Particularly Hazardous Substances" (PHS). OSHA defines these materials as "select" carcinogens, reproductive toxins and acutely toxic materials. Should you wish to add: explosive, violently reactive, pyrophoric and water-reactve materials to this category, the information is included. Carbon nanotubes have also been added due to their suspected carcinogenic properties. This table is designed to assist the laboratory in the identification of PHS, although it is not definitively conclusive or entirely comprehensive. *Notes on the proper use of this table appear on page 12. 1 6 5 2 3 4 Substance CAS National Toxicity National Program Carcinogen Toxin Acute Regulated OSHA Carcinogen Group IARC Carcinogen Toxin Reproductive Violently Reactive/ Explosive/Peroxide Forming/Pyrophoric A-a-C(2-Amino-9H-pyrido[2,3,b]indole) 2648-68-5 2B Acetal 105-57-7 yes Acetaldehyde 75-07-0 NTP AT 2B Acrolein (2-Propenal) 107-02-8 AT Acetamide 126850-14-4 2B 2-Acetylaminofluorene 53-96-3 NTP ORC Acrylamide 79-06-6 NTP 2B Acrylyl Chloride 814-68-6 AT Acrylonitrile 107-13-1 NTP ORC 2B Adriamycin 23214-92-8 NTP 2A Aflatoxins 1402-68-2 NTP 1 Allylamine 107-11-9 AT Alkylaluminums varies AT Allyl Chloride 107-05-1 AT ortho-Aminoazotoluene 97-56-3 NTP 2B para-aminoazobenzene 60-09-3 2B 4-Aminobiphenyl 92-67-1 NTP ORC 1 1-Amino-2-Methylanthraquinone 82-28-0 NTP (2-Amino-6-methyldipyrido[1,2-a:3’,2’-d]imidazole) 67730-11-4 2B
    [Show full text]
  • Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells
    Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells William N. Kelley, James B. Wyngaarden J Clin Invest. 1970;49(3):602-609. https://doi.org/10.1172/JCI106271. Research Article In the present study we have examined the effects of allopurinol and oxipurinol on thed e novo synthesis of purines in cultured human fibroblasts. Allopurinol inhibits de novo purine synthesis in the absence of xanthine oxidase. Inhibition at lower concentrations of the drug requires the presence of hypoxanthine-guanine phosphoribosyltransferase as it does in vivo. Although this suggests that the inhibitory effect of allopurinol at least at the lower concentrations tested is a consequence of its conversion to the ribonucleotide form in human cells, the nucleotide derivative could not be demonstrated. Several possible indirect consequences of such a conversion were also sought. There was no evidence that allopurinol was further utilized in the synthesis of nucleic acids in these cultured human cells and no effect of either allopurinol or oxipurinol on the long-term survival of human cells in vitro could be demonstrated. At higher concentrations, both allopurinol and oxipurinol inhibit the early steps ofd e novo purine synthesis in the absence of either xanthine oxidase or hypoxanthine-guanine phosphoribosyltransferase. This indicates that at higher drug concentrations, inhibition is occurring by some mechanism other than those previously postulated. Find the latest version: https://jci.me/106271/pdf Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells WILLIAM N. KELLEY and JAMES B. WYNGAARDEN From the Division of Metabolic and Genetic Diseases, Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina 27706 A B S TR A C T In the present study we have examined the de novo synthesis of purines in many patients.
    [Show full text]
  • Product Safety Summary
    Product Safety Summary Phosphorus Trichloride CAS No. 7719-12-2 This Product Safety Summary is intended to provide a general overview of the chemical substance. The information in the summary is basic information and is not intended to provide emergency response information, medical information or treatment information. The summary should not be used to provide in-depth safety and health information. In-depth safety and health information can be found in the Safety Data Sheet (SDS) for the chemical substance. Names Phosphorus trichloride Phosphorus (III) chloride Phosphorous chloride PCl 3 Product Overview Solvay Novecare does not sell phosphorus trichloride directly to consumers and phosphorus trichloride has no known uses except as an intermediate to produce other chemicals. Phosphorus trichloride (PCl3) is used as a chemical intermediate to produce a variety of products which are used in several applications including agricultural products, surfactants and metal extractants, flame retardants, additives for lubricants and stabilizers for plastics. Phosphorus trichloride is used in industrial applications and other processes where workplace exposures can occur. Consumer exposure does not occur as phosphorus trichloride is not used in any commercially available product. Phosphorus trichloride is dangerous to human health. Phosphorus trichloride may be fatal if inhaled, highly toxic if swallowed, harmful if absorbed through skin and can cause severe burns which may result in scarring. Phosphorus trichloride is consumed in manufacturing processes. PCl3 can make its way into the environment through unintentional releases (spills). PCl3 will not bioaccumulate but is not biodegradable. Based on ecotoxicological testing performed on fish and fresh-water invertebrates, PCl3 in higher concentrations can be harmful to aquatic life due to formation of acids from the hydrolysis of PCl3.
    [Show full text]
  • Competitive Inhibition of Beef Heart Cyclic AMP Phosphodiesterase by Cytokinins and Related Compounds (Cyclic AMP Metabolism/Intracellular Cyclic AMP Concentration)
    Proc. Nat. Acad. Sci. USA Vol. 71, No. 12, pp. 4670-4674, December 1974 Competitive Inhibition of Beef Heart Cyclic AMP Phosphodiesterase by Cytokinins and Related Compounds (cyclic AMP metabolism/intracellular cyclic AMP concentration) SIDNEY M. HECHT*, ROBERT D. FAULKNER, AND S. D. HAWRELAK Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Mass. 02139 Communicated by Nelson J. Leonard, September 9, 1974 ABSTRACT Two cytokinins and four related analogs, also shown to contain detectable adenylate cyclase activity, none of which is a cyclic ribonucleotide, have been shown suggesting that the cytokinins might function by raising the to act as competitive inhibitors of the high Km cyclic-AMP phosphodiesterase (3': 5'-cyclic-AMP 5'-nucleotidohydro- intracellular level of cyclic AMP (18). If operative in mouse lase, EC 3.1.4.1-7) activity from beef heart. Weak inhibition fibroblasts this phenomenon might also explain the observed of the low Km cyclic AMP phosphodiesterase activity was growth inhibition of such cells by cytokinins (S. M. Hecht and also observed, suggesting a possible mechanism for regula- R.. B. Frye, in preparation), since it has been shown that there tion of intracellular cyclic AMP levels by the exogenously added compounds. In addition to the kinetic data, ob- is an inverse relationship between intracellular cyclic AMP tained on the six inhibitors in four different heterocyclic concentration and growth in fibroblasts (19). series, 15 other cytokinins and related compounds have To further explore the apparent involvement of exogenously been shown to inhibit the high Km cyclic AMP phospho- added cytokinins in cyclic AMP metabolism, we have in- diesterase activity at single concentrations of substrate vestigated the kinetics of interaction of certain cytokinins, and and inhibitor.
    [Show full text]
  • UNITED STATES PATENT OFFICE 2,683,168 PREPARATHON of ORGANO PHOSPHONY, CHELORADES Warren Jensen, Ponca City, Okla., and James O
    Patented July 6, 1954 2,683,168 UNITED STATES PATENT OFFICE 2,683,168 PREPARATHON OF ORGANO PHOSPHONY, CHELORADES Warren Jensen, Ponca City, Okla., and James O. Claytoia, Berkeley, Calif., assigno's to California, Research Corporation, San Francisco, Calif., a corporation of Delaware No Drawing. Application December 22, 1950, Serial No. 202,396 8 Claims. (CI. 260-543) 1. 2 This invention relates to a method of prepar vide a means of preparing phosphonyl compounds ing phosphonyl chlorides and the like by the wherein the phosphorus atom is directly con reaction of an organic compound with phosphorus nected to an aliphatic carbon aton. trichloride in the presence of oxygen. it is another object of this invention to provide This application is a continuation-in-part of 5 a means of converting an aliphatic carbon-to Our Copending application, Serial No. 86,856 hydrogen bond to an aliphatic carbon-to-phoS (filed April 11, 1949 which has been abandoned, phorus bond. and was a continuation-in-part of application It is a further object of this invention to pro Serial No. 716,182 (filed December 12, 1946), which wide a more economical means of obtaining or has also been abandoned). O gano phosphorus compounds having a carbon-to Phosphonyl chloride and their derivatives are phosphorus linkage. useful in various arts. For example, certain It is a still further object of this invention to phosphonyl chloride derivatives (e.g., phosphonic provide a means of obtaining organo phosphorus acids and Salts and esters thereof) are useful compounds having
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Guanosine Item No. 27702 CAS Registry No.: 118-00-3 Synonyms: Guanine Ribonucleoside, NSC 19994 N O MF: C10H13N5O5 FW: 283.2 N O OH Purity: ≥98% N N UV/Vis.: λmax: 254 nm Supplied as: A crystalline solid H OH OH H N Storage: -20°C 2 Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Guanosine is supplied as a crystalline solid. A stock solution may be made by dissolving the guanosine in the solvent of choice, which should be purged with an inert gas. Guanosine is soluble in the organic solvent DMSO at a concentration of approximately 30 mg/ml. Guanosine is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, guanosine should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Guanosine has a solubility of approximately 0.16 mg/ml in a 1:5 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Guanosine is a purine nucleoside that is comprised of the purine base guanine attached to a ribose moiety.1 Mono-, di-, tri-, and cyclic monophosphorylated forms of guanosine (GMP, GDP, GTP, and cGMP, respectively) are essential for a variety of endogenous biochemical processes, such as signal transduction, metabolism, and RNA synthesis.2-4 References 1. Voet, D. and Voet, J.G. 3rd ed., John Wiley & Sons, Hoboken, NJ (2004). 2. Hanson, R.W. and Garber, A.J.
    [Show full text]
  • Bureau of Industry and Security, Commerce Pt. 742, Supp. 1
    Bureau of Industry and Security, Commerce Pt. 742, Supp. 1 that an export or reexport could make N,N-diethylethanolamine is December 12, a significant contribution to the mili- 1989. tary potential of North Korea, includ- (6) The contract sanctity date for exports ing its military logistics capability, or to all destinations (except Iran or Syria) of could enhance North Korea’s ability to phosphorus trichloride, trimethyl phosphite, support acts of international ter- and thionyl chloride is December 12, 1989. rorism, the Secretaries of State and For exports to Iran or Syria, paragraph (2) of Commerce will notify the Congress 30 this supplement applies. days prior to issuance of a license. (7) The contract sanctity date for exports to all destinations (except Iran or Syria) of [65 FR 38151, June 19, 2000, as amended at 66 2-chloroethanol and triethanolamine is Jan- FR 36682, July 12, 2001; 68 FR 16212, Apr. 3, uary 15, 1991. For exports of 2-chloroethanol 2003; 70 FR 54628, Sept. 16, 2005; 71 FR 20885, to Iran or Syria, paragraph (1) of this Sup- Apr. 24, 2006; 72 FR 3725, Jan. 26, 2007; 72 FR plement applies. For exports of triethanol- 62532, Nov. 5, 2007; 75 FR 14340, Mar. 25, 2010] amine to Iran or Syria, paragraph (5) of this Supplement applies. SUPPLEMENT NO. 1 TO PART 742—NON- (8) The contract sanctity date for exports PROLIFERATION OF CHEMICAL AND BI- to all destinations (except Iran or Syria) of OLOGICAL WEAPONS chemicals controlled by ECCN 1C350 is March 7, 1991, except for applications to export the NOTE: Exports and reexports of items in performance of contracts entered into before following chemicals: 2-chloroethanol, di- the applicable contract sanctity date(s) will methyl methylphosphonate, dimethyl be eligible for review on a case-by-case basis phosphite (dimethyl hydrogen phosphite), or other applicable licensing policies that phosphorus oxychloride, phosphorous tri- were in effect prior to the contract sanctity chloride, thiodiglycol, thionyl chloride tri- date.
    [Show full text]
  • United States Patent Office Patented Aug
    3,463,840 United States Patent Office Patented Aug. 26, 1969 1. 2 phonates in small yields. When at least three moles of mer 3,463,840 captan are employed, the alkylthioalkyldithiophospho PROCESS FOR PRODUCING ALKYLTHOALKYL nates are obtained in good yields. PHOSPHONODTHOC ESTERS Alkylthioalkyldithiophosphonates are known com Marion F. Botts, Independence, Mo., and Erik K. Regel, Mission, Kans, assignors to Chemagro Corporation, pounds and are useful as defoliants, Regal patent 3,193,- New York, N.Y., a corporation of New York 372. The procedure for preparing such compounds in the No Drawing. Original application June 24, 1966, Ser. No. Regal patent, namely reacting PCls with a hydrocarbon 560,097. Divided and this application Jan. 3, 1968, Ser. and a disulfide in the presence of a Friedel-Crafts catalyst, No. 708,745 however, is relatively expensive considering the overall Int, Cl, C07f 9/40, A01n 9/36 O yields and reaction conditions employed. U.S. C. 260-972 8 Claims Accordingly, it is an object of the present invention to develop a novel method for making alkylthioalkyldithio phosphonates. ABSTRACT OF THE DISCLOSURE Another object is to develop a novel method for Compounds are prepared having the formula 5 making analogues of alkylthioalkyldithiophosphonates wherein the alkyl thio group is replaced by haloalkylthio. O SR3 A further object is to develop a method of preparing RSCIP N dithiophosphonates which cannot be synthesized by other R SR4 routes. where R, Ra, and R4 are alkyl or monohaloalkyl and R2 20 An additional object is to develop a novel method for is hydrogen, alkyl, monohaloalkyl, aryl, haloaryl or al killing nematodes.
    [Show full text]
  • RNA Transcription (UV-Induced Crosslinkdng/Two-Dimensional Gel Electrophoresis) ISMO ULMANEN, BARBARA A
    Proc. Nati Acad. Sci. USA Vol. 78, No. 12, pp. 7355-7359, December 1981 Biochemistry Role of two of the influenza virus core P proteins in recognizing cap 1 structures (m7GpppNm) on RNAs and in initiating viral RNA transcription (UV-induced crosslinkdng/two-dimensional gel electrophoresis) ISMO ULMANEN, BARBARA A. BRONI, AND ROBERT M. KRUG Molecular Biology and Genetics Unit of the Graduate School, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 Communicated by Aaron J. Shatkin, August 21, 1981 ABSTRACT Purified influenza viral cores catalyze the entire triphosphate (6). This guanosine incorporation is apparently process of viral RNA transcription, which includes the endo- directed by the penultimate cytosine residue at the 3' end of nucleolytic cleavage of heterologous RNAs containing cap 1 the eight virion RNA (vRNA) templates (6). In the presence of (m7GpppNm) structures to generate capped primers 10-13 nu- all four triphosphates, the viral RNA transcripts are then cleotides long, the initiation oftranscription via the incorporation elongated. ofa guanosine residue onto the primers, and elongation ofthe viral This entire reaction is catalyzed by purified viral cores (nu- mRNAs [Plotch, S. J., Bouloy, M., Ulmanen, I. & Krug, R. M. cleocapsids) (6), which contain four known virus-specific pro- (1980) Cell 23, 847-858]. To identify which viral core protein (nu- teins: the nucleocapsid protein (NP), which constitutes the cleocapsid protein, P1, P2, or P3) recognizes the cap 1 structure majority (about 92%) of the protein, and the three P proteins on the RNA primer, we irradiated (UV) endonuclease reactions (6, 7). Studies with temperature-sensitive virus mutants indi- carried out by viral cores in the absence of ribonucleoside tri- that at least two of these P proteins are required for tran- phosphates, with a primer RNA labeled in its cap 1 structure with cate mo- scription (8, 9).
    [Show full text]